Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Analyst Perspectives | Learn about Abbott's average price target of $143, with estimates ranging from $133 to $159, reflecting varied views on its growth potential and market dynamics. |
Innovation Leadership | Delve into Abbott's product breakthroughs, including the PFA System's early European approval and exceptional growth in diabetes care, driving market position. |
Financial Fortitude | Explore Abbott's robust financial metrics, including $42.3B revenue, 56% gross margin, and 31% ROE, with 2025 guidance projecting 7.5-8.5% top-line growth. |
Diversified Dominance | Abbott's multi-segment portfolio drives resilience, with strong organic growth and a 3.2 Financial Health Score, positioning it well in the healthcare sector. |
Metrics to compare | ABT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABTPeersSector | |
---|---|---|---|---|
P/E Ratio | 15.4x | −12.0x | −0.5x | |
PEG Ratio | 0.10 | −0.31 | 0.00 | |
Price / Book | 4.4x | 4.9x | 2.6x | |
Price / LTM Sales | 5.0x | 3.7x | 3.2x | |
Upside (Analyst Target) | 15.3% | 43.8% | 44.3% | |
Fair Value Upside | Unlock | −22.9% | 6.6% | Unlock |